Literature DB >> 3390499

Alteration of platelet serotonergic mechanisms and monoamine oxidase activity in premenstrual syndrome.

C R Ashby1, L A Carr, C L Cook, M M Steptoe, D D Franks.   

Abstract

Platelet uptake and content of 5-hydroxytryptamine (5-HT), platelet monoamine oxidase (MAO) activity, and plasma free and total tryptophan levels were determined in patients diagnosed with premenstrual syndrome (PMS) and in control subjects. The Vmax of 5-HT uptake and 5-HT content in platelets of PMS patients were significantly decreased during the premenstrual phase (cycle days -9 to -1) compared to control subjects. Platelet MAO activity was significantly lower postmenstrually (cycle days 5-9) in PMS patients compared to the premenstrual phase. There were no differences in plasma free and total tryptophan levels between PMS patients and control subjects during either interval. As platelets are believed to be a peripheral model for central serotonergic neurons, the results suggest that PMS symptomatology may be related to alterations in serotonergic neuronal mechanisms.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3390499     DOI: 10.1016/0006-3223(88)90277-6

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  12 in total

Review 1.  The pathophysiologic background for current treatments of premenstrual syndromes.

Authors:  Uriel Halbreich
Journal:  Curr Psychiatry Rep       Date:  2002-12       Impact factor: 5.285

Review 2.  Premenstrual syndrome as a criminal defense.

Authors:  J W Lewis
Journal:  Arch Sex Behav       Date:  1990-10

Review 3.  On the physiology of metazoa.

Authors:  A R Ameen
Journal:  Experientia       Date:  1996-03-15

Review 4.  The role of central serotonergic dysfunction in the aetiology of premenstrual dysphoric disorder: therapeutic implications.

Authors:  B L Parry
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

5.  The efficacy of Hypericum perforatum (St John's wort) for the treatment of premenstrual syndrome: a randomized, double-blind, placebo-controlled trial.

Authors:  Sarah Canning; Mitch Waterman; Nic Orsi; Julie Ayres; Nigel Simpson; Louise Dye
Journal:  CNS Drugs       Date:  2010-03       Impact factor: 5.749

6.  Alteration of 5-HT uptake by plasma fractions in the premenstrual syndrome.

Authors:  C R Ashby; L A Carr; C L Cook; M M Steptoe; D D Franks
Journal:  J Neural Transm Gen Sect       Date:  1990

Review 7.  Reproductive hormone sensitivity and risk for depression across the female life cycle: a continuum of vulnerability?

Authors:  Claudio N Soares; Brook Zitek
Journal:  J Psychiatry Neurosci       Date:  2008-07       Impact factor: 6.186

Review 8.  A risk-benefit appraisal of drugs used in the management of premenstrual syndrome.

Authors:  J F Mortola
Journal:  Drug Saf       Date:  1994-02       Impact factor: 5.606

9.  Premenstrual Dysphoric Disorder: Recognition and Treatment.

Authors:  Ellen W. Freeman; Steven J. Sondheimer
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2003-02

10.  Serotonergic function and late luteal phase dysphoric disorder.

Authors:  A T Veeninga; H G Westenberg
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.